MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-16-2026
Regulus Therapeutics Operating Cash Flow 2011-2026 | RGLS
Annual Operating Cash Flow Regulus Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -41.7 M | -26.8 M | -25.5 M | -24.1 M | -12.5 M | -19.8 M | -43.3 M | -58.8 M | -56.9 M | -49.9 M | -39.5 M | -28.3 M | -8.72 M | -15.1 M | 12.3 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.3 M | -58.8 M | -29.2 M |
Quarterly Operating Cash Flow Regulus Therapeutics
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.6 M | - | - | - | -8.74 M | - | - | - | -8.11 M | - | - | -12.5 M | -6.38 M | - | - | -10.7 M | -5.71 M | - | -15.7 M | -11.2 M | -6 M | - | -14.8 M | -10.1 M | -4.43 M | - | -39.3 M | -27.8 M | -15.6 M | - | -47.7 M | -36 M | -18.7 M | - | -41.8 M | -26.3 M | -8.93 M | - | -32.8 M | -21 M | -11.3 M | - | - | - | -9.03 M | - | - | - | -7.16 M | - | -9.57 M | -9.8 M | -5.13 M | - | -9.58 M | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.43 M | -47.7 M | -16.2 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-8.24 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.57 | -3.68 % | $ 184 M |  USA |
 |
Happiness Biotech Group Limited
HAPP
|
-2.67 M | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
156 M | $ 16.87 | -2.49 % | $ 789 M | USA |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
14.6 B | - | - | $ 96.9 B |  Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
-74.3 M | $ 7.47 | -4.6 % | $ 205 M |  Israel |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-24.5 M | - | 0.74 % | $ 768 M | Israel |
 |
Eton Pharmaceuticals
ETON
|
10.5 M | $ 30.26 | 1.0 % | $ 814 M | USA |
 |
Galera Therapeutics
GRTX
|
-6.05 M | - | -32.59 % | $ 7.61 M | USA |
 |
Exelixis
EXEL
|
884 M | $ 50.13 | -1.9 % | $ 13.6 B | USA |
 |
Fortress Biotech
FBIO
|
-65.8 M | $ 2.41 | 4.78 % | $ 67.2 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.59 M | - | -18.52 % | $ 27.3 M | Britain |
|
Forte Biosciences
FBRX
|
-50.9 M | $ 23.11 | -3.55 % | $ 299 M | USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 4.09 | -7.05 % | $ 1.22 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.63 | 2.52 % | $ 434 M | Britain |
 |
BioNTech SE
BNTX
|
456 M | $ 89.55 | -2.65 % | $ 21.6 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Galectin Therapeutics
GALT
|
-23.9 M | $ 2.17 | -7.66 % | $ 139 M | USA |
 |
Celyad Oncology SA
CYAD
|
-28 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
-88.6 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-35.1 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Gilead Sciences
GILD
|
10 B | $ 129.58 | -1.88 % | $ 161 B | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.36 | -3.72 % | $ 5.53 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-8.47 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-10.4 M | $ 0.72 | -1.58 % | $ 32.9 M | Israel |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | $ 3.12 | - | $ 649 M | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Genmab A/S
GMAB
|
7.77 B | $ 26.54 | -1.34 % | $ 1.72 B |  Danmark |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-93.6 M | - | - | $ 28.6 M | USA |